Acknowledgement
Supported by : Hanyang University
References
- Issa SN, Sharma L. Epidemiology of osteoarthritis: an update. Curr Rheumatol Rep 2006;8:7-15. https://doi.org/10.1007/s11926-006-0019-1
- Martel-Pelletier J, Boileau C, Pelletier JP, Roughley PJ. Cartilage in normal and osteoarthritis conditions. Best Pract Res Clin Rheumatol 2008;22:351-384. https://doi.org/10.1016/j.berh.2008.02.001
- Goldring SR, Goldring MB. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 2004;(427 Suppl):S27-S36.
- American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905-1915. https://doi.org/10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P
- Cameron M, Gagnier JJ, Little CV, Parsons TJ, Blumle A, Chrubasik S. Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part I: osteoarthritis. Phytother Res 2009;23:1497-1515. https://doi.org/10.1002/ptr.3007
- Choi JH, Choi JH, Kim DY, et al. Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase-induced rabbit osteoarthritis model. Osteoarthritis Cartilage 2002;10:471-478. https://doi.org/10.1053/joca.2002.0526
- Kim JH, Ryu KH, Jung KW, Han CK, Kwak WJ, Cho YB. SKI306X suppresses cartilage destruction and inhibits the production of matrix metalloproteinase in rabbit joint cartilage explant culture. J Pharmacol Sci 2005;98:298-306. https://doi.org/10.1254/jphs.FPJ04058X
- Hartog A, Hougee S, Faber J, et al. The multicomponent phytopharmaceutical SKI306X inhibits in vitro cartilage degradation and the production of inflammatory mediators. Phytomedicine 2008;15:313-320. https://doi.org/10.1016/j.phymed.2007.09.005
- Jung YB, Roh KJ, Jung JA, et al. Effect of SKI 306X, a new herbal anti-arthritic agent, in patients with osteoarthritis of the knee: a double-blind placebo controlled study. Am J Chin Med 2001;29:485-491. https://doi.org/10.1142/S0192415X01000502
- Lung YB, Seong SC, Lee MC, et al. A four-week, randomized, double-blind trial of the efficacy and safety of SKI306X: a herbal anti-arthritic agent versus diclofenac in osteoarthritis of the knee. Am J Chin Med 2004;32:291-301. https://doi.org/10.1142/S0192415X04001941
- Billinghurst RC, Dahlberg L, Ionescu M, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-1545. https://doi.org/10.1172/JCI119316
- Song YW, Lee EY, Koh EM, et al. Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double- dummy, phase III, noninferiority clinical trial. Clin Ther 2007;29:862-873. https://doi.org/10.1016/j.clinthera.2007.05.006
- Uitterlinden EJ, Jahr H, Koevoet JL, et al. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthritis Cartilage 2006;14:250-257. https://doi.org/10.1016/j.joca.2005.10.001
- Koshy PJ, Lundy CJ, Rowan AD, et al. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum 2002;46:961-967. https://doi.org/10.1002/art.10212
- Wachsmuth L, Bau B, Fan Z, Pecht A, Gerwin N, Aigner T. ADAMTS-1, a gene product of articular chondrocytes in vivo and in vitro, is downregulated by interleukin 1beta. J Rheumatol 2004;31:315-320.
- Rogerson FM, Chung YM, Deutscher ME, Last K, Fosang AJ. Cytokine-induced increases in ADAMTS-4 messenger RNA expression do not lead to increased aggrecanase activity in ADAMTS-5-deficient mice. Arthritis Rheum 2010;62:3365-3373. https://doi.org/10.1002/art.27661
- Lauer-Fields JL, Spicer TP, Chase PS, et al. Screening of potential a disintegrin and metalloproteinase with thrombospondin motifs-4 inhibitors using a collagen model fluorescence resonance energy transfer substrate. Anal Biochem 2008;373:43-51. https://doi.org/10.1016/j.ab.2007.09.014
- Fosang AJ, Little CB. Drug insight: aggrecanases as therapeutic targets for osteoarthritis. Nat Clin Pract Rheumatol 2008;4:420-427.
- Lauer-Fields JL, Minond D, Chase PS, et al. High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem 2009;17:990-1005. https://doi.org/10.1016/j.bmc.2008.03.004
- Li NG, Shi ZH, Tang YP, et al. New hope for the treatment of osteoarthritis through selective inhibition of MMP-13. Curr Med Chem 2011;18:977-1001. https://doi.org/10.2174/092986711794940905
- Verma P, Dalal K. ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis. J Cell Biochem 2011;112:3507-3514. https://doi.org/10.1002/jcb.23298
Cited by
- Anticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions vol.18, pp.1, 2014, https://doi.org/10.2174/1389202917666160803151752
- Efficacy of JOINS on Cartilage Protection in Knee Osteoarthritis: Prospective Randomized Controlled Trial vol.29, pp.3, 2014, https://doi.org/10.5792/ksrr.17.004
- Comparison of pharmacokinetics and safety of fixed-dose combination of SKI306X and aceclofenac versus separate tablets in healthy subjects vol.25, pp.4, 2014, https://doi.org/10.12793/tcp.2017.25.4.196
- Polar extract of Curcuma longa protects cartilage homeostasis: possible mechanism of action vol.26, pp.5, 2018, https://doi.org/10.1007/s10787-017-0433-1
- Pharmaceutical therapeutics for articular regeneration and restoration: state-of-the-art technology for screening small molecular drugs vol.78, pp.24, 2014, https://doi.org/10.1007/s00018-021-03983-8